A month after Genentech confirmed the restructuring of its early development group, the Roche subsidiary has now disclosed that this has formed part of a round of 103 layoffs.
Source: FierceBiotech
You may also like
Cancer, immune drugmakers dominate VC funding so far...
Beyond Boston: Unlikely cities stake biotech claims
Vera Therapeutics wins FDA nod for closely watched...
Gene editing developer Scribe plots an IPO
Novartis to acquire ADC developer in a deal worth up...
Exact Imaging boosts U.S. commercial team for next-gen...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.